Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.

Richard J KnightEdward A GravissDuc T NguyenSamantha A KutenSamir J PatelLillian GaberA Osama Gaber

Published in: Clinical transplantation (2018)

Conversion from TAC/MMF into TAC/mTOR immunosuppression after KP transplantation reduced the incidences of BK and CMV viremia with an equivalent risk of acute rejection and similar renal/pancreas function.

Keyphrases

cell proliferation
liver failure
cell therapy
respiratory failure
risk factors
drug induced
stem cells
mesenchymal stem cells
intensive care unit
bone marrow
extracorporeal membrane oxygenation
mechanical ventilation